Literature DB >> 25600761

Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.

Rana R McKay1, Khalid Mamlouk2, Bruce Montgomery3, Mary-Ellen Taplin4.   

Abstract

Entities:  

Keywords:  Androgen receptor; Androgen signaling; Anti-androgen; CYP17 inhibitor; Hormone therapy

Mesh：

Substances：

Year:  2014        PMID： 25600761      PMCID： PMC4563804          DOI： 10.1016/j.clgc.2014.12.015

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  20 in total

1.  Mechanisms of androgen-refractory prostate cancer.

Authors:  Jose D Debes; Donald J Tindall
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 2.  Mechanisms underlying the development of androgen-independent prostate cancer.

Authors:  Kenneth J Pienta; Deborah Bradley
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

Review 3.  Androgen receptor splice variants in the era of enzalutamide and abiraterone.

Authors:  Mary Nakazawa; Emmanuel S Antonarakis; Jun Luo
Journal:  Horm Cancer       Date:  2014-07-22       Impact factor: 3.869

4.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

Authors:  L F Hutchins; J M Unger; J J Crowley; C A Coltman; K S Albain
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

5.  Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies.

Authors:  S Monfardini; R Sorio; G H Boes; S Kaye; D Serraino
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 7.  The link between androgen receptor splice variants and castration-resistant prostate cancer.

Authors:  Cynthia C T Sprenger; Stephen R Plymate
Journal:  Horm Cancer       Date:  2014-05-06       Impact factor: 3.869

8.  Participation of patients 65 years of age or older in cancer clinical trials.

Authors:  Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

Review 9.  Guidelines for the treatment of elderly cancer patients.

Authors:  Stuart M Lichtman
Journal:  Cancer Control       Date:  2003 Nov-Dec       Impact factor: 3.302

10.  Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Authors:  Tadas Vasaitis; Aashvini Belosay; Adam Schayowitz; Aakanksha Khandelwal; Pankaj Chopra; Lalji K Gediya; Zhiyong Guo; Hong-Bin Fang; Vincent C O Njar; Angela M H Brodie
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261
View more
  1 in total

1.  Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.

Authors:  Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Vidya P Ramamurthy; Puranik Purushottamachar; Francis N Murigi; Tadas S Vasaitis; Weiliang Huang; Maureen A Kane; Yuji Zhang; Nicholas Ambulos; Sudhir Tiwari; Pratima Srivastava; Ivo P Nnane; Arif Hussain; Yun Qiu; David J Weber; Vincent C O Njar
Journal:  Cancers (Basel)       Date:  2019-10-24       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.